Pancreatic cancer risk (GLP-1 myth check)

Definition

An early concern from rodent studies (acinar-cell hyperplasia in some animal models). Large human cohort studies and the SELECT cardiovascular outcomes trial (Lincoff 2023, PMID 37952131) have NOT shown an elevated pancreatic-cancer signal over years of follow-up. The 2024 FDA Drug Safety Communication confirmed no causal association established. The boxed warning on GLP-1 labels covers thyroid C-cell tumors (rodent data) and acute pancreatitis (small absolute risk), but NOT pancreatic cancer.

SELECT trial deep-dive (long-term safety) →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in Side effects

• Cholelithiasis
• Ileus
• Telogen effluvium
• Ozempic face
• Medullary thyroid carcinoma (MTC)
• Lean mass loss
• GLP-1-induced gastroparesis
• Pancreatitis (acute)

Looking for more depth?

• SELECT trial deep-dive (long-term safety)
• Browse the full GLP-1 glossary (71 terms across 8 categories)
• Research articles — primary-source deep dives
• Tools and calculators
• Compare GLP-1 telehealth providers